sur TuHURA Biosciences, Inc.
TuHURA Biosciences (Nasdaq: HURA) Presents at Maxim Healthcare Virtual Summit
On October 23, 2024, TuHURA Biosciences, Inc., an immune-oncology company listed on Nasdaq as HURA, announced their participation in the 2024 Maxim Healthcare Virtual Summit. The event, hosted by Maxim Group LLC, featured Dr. James Bianco, TuHURA's President and CEO, who took part in the Precision and Immune Oncology panel discussion.
TuHURA is in the Phase 3 registration stage, focusing on novel technologies to overcome resistance to cancer immunotherapy. Their leading candidate, IFx-2.0, targets primary resistance to checkpoint inhibitors. A Phase 3 trial of IFx-2.0, alongside Keytruda® for Merkel Cell Carcinoma, is in preparation.
The company is also advancing its Delta receptor technology to develop bi-specific ADCs and PDCs aimed at suppressing immune inhibitory effects in the tumor microenvironment.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de TuHURA Biosciences, Inc.